Pancreatic Cancer Research

Journal articleNAR Cancer2020

A novel siRNA-gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer.

Journal
NAR Cancer
Published
11 August 2020
Citations
7
Type
Article
License
cc by-nc

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract cc by-nc

The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant toxicity for the patient. … Excerpt only: this text is the publisher’s. Read it in full at the source.